Tidalsense raised $19 million to scale N-Tidal Diagnose, an AI-based platform designed to identify chronic obstructive pulmonary disease in about five minutes. The company’s approach focuses on rapid, bedside-style diagnostics rather than lab-dependent workflows. The financing indicates continued investor interest in AI-driven point-of-care respiratory testing, where speed and accessibility can change clinical throughput and treatment initiation. The round also highlights how diagnostic startups are moving beyond model development into deployment-ready products that can be validated in real-world clinical settings.